Clinerion patient recruitment system selected as official service for ICN members

By Melissa Fassbender

- Last updated on GMT

Up to 50% of all delays and 30% of phase III terminations are caused by slow recruitment. (Image: iStock/Weedezign)
Up to 50% of all delays and 30% of phase III terminations are caused by slow recruitment. (Image: iStock/Weedezign)

Related tags Patient recruitment Clinical trial

The International Clinical Trial Center Network (ICN) adopts Clinerion's patient recruitment system as an official service to help its members speed trail startup.

Clinerion’s system brings automated medical informatics solutions for protocol design, site selection, and patient recruitment​ to members of the ICN – a network of academic and government-based research institutions worldwide.

According to Ulf Claesson, Clinerion’s CEO, what makes the patient recruitment system (PRS) unique is a combination of three elements: “real-time search (so patients can be identified as they arrive at the hospital), a hybrid network of federated local installations at hospitals, and complete protocol definition and feasibility check​,” he told Outsourcing-Pharma.com.

Hospitals can get more visibility for having trials sited, leading to more revenue from trials and a better reputation for research, without having to develop their own query systems​,” added Claesson.

Through automation Clinerion is able to identify candidate patients​ and their locations in minutes, speeding up site selection and discussions with trial sites on placing the trials. With traditional methods, 48% of sites miss their enrollment targets for Phase II or III studies, resulting in timelines nearly double the original duration to meet desired enrollment levels.

Additionally, through the PRS protocols can be checked in real-time, removing the need for many protocol amendments iterations, which can be extremely costly​, with each amendment costing an estimated $450,000 – and often more than 3.5 amendments are required for Phase III trial protocols.

Each day a drug is delayed from reaching the market, the pharmaceutical company loses up to $8 million​,” added Claesson, and up to 50% of all delays and 30% of phase III terminations are caused by slow recruitment.

We are grateful to the ICN for adopting us, as it means that the premier research hospitals of the world have acknowledged the benefits PRS brings to the clinical trials process​,” said Claesson.

Related news

Show more

Related products

show more

Saama accelerates data review processes

Saama accelerates data review processes

Content provided by Saama | 25-Mar-2024 | Infographic

In this new infographic, learn how Saama accelerates data review processes. Only Saama has AI/ML models trained for life sciences on over 300 million data...

More Data, More Insights, More Progress

More Data, More Insights, More Progress

Content provided by Saama | 04-Mar-2024 | Case Study

The sponsor’s clinical development team needed a flexible solution to quickly visualize patient and site data in a single location

Using Define-XML to build more efficient studies

Using Define-XML to build more efficient studies

Content provided by Formedix | 14-Nov-2023 | White Paper

It is commonly thought that Define-XML is simply a dataset descriptor: a way to document what datasets look like, including the names and labels of datasets...

Related suppliers

Follow us

Webinars

Headlines